Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 11, 2012, Pages 1117-1124

  Mallia, Patrick ^a,b,c   Footitt, Joseph ^a,b,c   Sotero, Rosa ^a,d   Jepson, Annette ^b   Contoli, Marco ^a,e   Trujillo Torralbo, Maria Belen ^a,b   Kebadze, Tatiana ^a   Aniscenko, Julia ^a   Oleszkiewicz, Gregory ^a   Gray, Katrina ^a,b   Message, Simon D ^a   Ito, Kazuhiro ^a   Barnes, Peter J ^a   Adcock, Ian M ^a   Papi, Alberto ^e   Stanciu, Luminita A ^a   Elkin, Sarah L ^a,b   Kon, Onn M ^a,b,c   Johnson, Malcolm ^f   Johnston, Sebastian L ^a,b,c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c Centre for Respiratory Infections   (United Kingdom)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bacteria; Chronic obstructive pulmonary disease; Disease exacerbation; Rhinovirus

Indexed keywords

ALPHA DEFENSIN; BETA DEFENSIN; ELAFIN; PENTRAXIN; POLYPEPTIDE ANTIBIOTIC AGENT;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FEMALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RHINOVIRUS INFECTION; SMOKING; SPUTUM ANALYSIS; VIRUS LOAD;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL INFECTIONS; C-REACTIVE PROTEIN; COHORT STUDIES; COINFECTION; DISEASE PROGRESSION; ELAFIN; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PICORNAVIRIDAE INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RHINOVIRUS; RISK ASSESSMENT; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SERUM AMYLOID P-COMPONENT; SEVERITY OF ILLNESS INDEX; SMOKING; SPUTUM; STATISTICS, NONPARAMETRIC;

EID: 84870407475     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201205-0806OC     Document Type: Article

References (36)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
2. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
3. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
4. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, The GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
5. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121.
6. Hutchinson AF, Ghimire AK, Thompson MA, Black JF, Brand CA, Lowe AJ, Smallwood DM, Vlahos R, Bozinovski S, Brown GV, et al. A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. Respir Med 2007;101:2472-2481.
7. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012;379:1341-1351.
8. Cameron RJ, de Wit D, Welsh TN, Ferguson J, Grissell TV, Rye PJ. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. Intensive Care Med 2006;32:1022-1029.
9. Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, Rutschmann OT. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest 2010;138:896-904.
10. Sajjan U, Wang Q, Zhao Y, Gruenert DC, Hershenson MB. Rhinovirus disrupts the barrier function of polarized airway epithelial cells. Am J Respir Crit Care Med 2008;178:1271-1281.
11. Wang JH, Kwon HJ, Jang YJ. Rhinovirus enhances various bacterial adhesions to nasal epithelial cells simultaneously. Laryngoscope 2009;119:1406-1411.
12. Oliver BG, Lim S, Wark P, Laza-Stanca V, King N, Black JL, Burgess JK, Roth M, Johnston SL. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax 2008;63:519-525.
13. Peltola V, Heikkinen T, Ruuskanen O, Jartti T, Hovi T, Kilpi T, Vainionpää R. Temporal association between rhinovirus circulation in the community and invasive pneumococcal disease in children. Pediatr Infect Dis J 2011;30:456-461.
14. Mallia P, Message SD, Kebadze T, Parker HL, Kon OM, Johnston SL. An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir Res 2006;7:116.
15. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, Aniscenko J, Laza-Stanca V, Edwards MR, Slater L, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011;183:734-742.
16. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, Davies J, Ervine A, Poulter L, Pachter L, et al. Disordered microbial communities in asthmatic airways. PLoS ONE 2010;5:e8578.
17. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, Young VB, Toews GB, Curtis JL, Sundaram B, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS ONE 2011;6:e16384.
18. Sallenave JM. Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity. Am J Respir Cell Mol Biol 2010;42:635-643.
19. Footitt J, Mallia P, Sotero R, Trujillo-Torralbo MB, Kebadze T, Contoli M, Papi A, Kon OM, Maselli R, Johnston SL. Rhinovirus infection upregulates pentraxin-3 in smokers and COPD patients. European Respiratory Society Congress 2011. Abstract 199.
20. Sotero R, Mallia P, Footitt J, Trujillo-Torralbo MB, Kebadze T, Contoli M, Papi A, Pelaia G, Maselli R, Johnston SL. Induction of cathelicidin (LL-37) in rhinovirus-induced COPD exacerbations. European Respiratory Society Congress 2011.P3015.
21. Mallia P, Footitt J, Trujillo-Torralbo MB, Oleszkiewicz G, Omolu A, Contoli M, Message S, Papi A, Johnston SL, Kon OM. Bacterial infections following experimental rhinovirus infection In COPD. Am J Respir Crit Care Med 2011;183:A3728.
22. Mallia P, Footitt J, Sotero R, Jepson A, Oleszkiewicz G, Aniscenko J, Kon OM, Papi A, Johnston SL, Pelaia G. Rhinovirus infection induces secondary bacterial infection in COPD. European Respiratory Society Congress 2011. Abstract 196.
23. Bardin PG, Sanderson G, Robinson BS, Holgate ST, Tyrrell DA. Experimental rhinovirus infection in volunteers. Eur Respir J 1996;9:2250-2255.
24. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebadze T, Contoli M, Sanderson G, Kon OM, Papi A, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci USA 2008;105:13562-13567.
25. Pizzichini E, Pizzichini MM, Leigh R, Djukanovi R, Sterk PJ. Safety of sputum induction. Eur Respir J Suppl 2002;37:9s-18s.
26. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:554-564.
27. Weldon S, McNally P, McElvaney NG, Elborn JS, McAuley DF, Wartelle J, Belaaouaj A, Levine RL, Taggart CC. Decreased levels of secretory leucoprotease inhibitor in the pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol 2009;183:8148-8156.
28. Guyot N, Butler MW, McNally P, Weldon S, Greene CM, Levine RL, O'Neill SJ, Taggart CC, McElvaney NG. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem 2008;283:32377-32385.
29. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-1623.
30. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biological clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-671.
31. Parameswaran GI, Wrona CT, Murphy TF, Sethi S. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis 2009;9:178.
32. Parameswaran GI, Sethi S, Murphy TF. Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD. Chest 2011;140:611-617.
33. Pant S, Walters EH, Griffiths A, Wood-Baker R, Johns DP, Reid DW. Airway inflammation and anti-protease defenses rapidly improve during treatment of an acute exacerbation of COPD. Respirology 2009;14:495-503.
34. Herr C, Beisswenger C, Hess C, Kandler K, Suttorp N, Welte T, Schroeder JM, Vogelmeier C. Suppression of pulmonary innate host defense in smokers. Thorax 2009;64:144-149.
35. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, MacNee W, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.
36. Zalacain R, Sobradillo V, Amilibia J, Barron J, Achotegui V, Pijoan JI, Llorente JL. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999;13:343-348.